The Potential of Ivermectin: Exploring Its Re-Purpose Case In Oncology

by | Feb 12, 2025 | Health | 0 comments

Ivermectin, a widely used antiparasitic drug, has gained attention in recent years for its potential to be repurposed in cancer treatment. Originally developed to combat parasitic infections in both humans and in animals. The use of ivermectin outside of its original intention has demonstrated anticancer properties in early pre-clinical studies. While it has not yet been approved for cancer treatment, there is emerging research suggesting that it could really complement existing therapies and provide an alternative approach for certain types of cancer.

The Mechanism of Ivermectin in Cancer Therapy

Ivermectin appears to exert anticancer effects through multiple mechanisms, including:

  • Inducing Apoptosis (Programmed Cell Death): Studies suggest that ivermectin can trigger apoptosis in cancer cells by inhibiting key survival pathways.
  • Inhibiting Cancer Cell Proliferation: Research has shown that ivermectin interferes with cancer cell growth by disrupting various signaling pathways, such as the WNT/β-catenin and Hippo pathways, which are involved in tumor progression.
  • Targeting Cancer Stem Cells: Cancer stem cells contribute to tumor growth and resistance to treatment. Ivermectin has been shown to reduce the viability of these cells, making it a promising candidate for preventing cancer recurrence.
  • Enhancing Chemosensitivity: Some studies suggest that ivermectin can enhance the effectiveness of chemotherapy drugs by overcoming drug resistance mechanisms.

Potential Applications for Different Cancer Types

Preclinical studies have explored ivermectin’s effects on various cancers, including:

  • Breast Cancer: Research indicates that ivermectin can inhibit breast cancer cell growth and enhance sensitivity to chemotherapy.
  • Lung Cancer: Studies suggest that ivermectin may suppress lung cancer progression by modulating key signaling pathways.
  • Colorectal Cancer: Ivermectin has been shown to reduce the viability of colorectal cancer cells and enhance the effects of other anticancer agents.
  • Leukemia: Research suggests ivermectin can induce apoptosis in leukemia cells, offering potential for blood cancer treatment.
  • Glioblastoma: Due to its ability to cross the blood-brain barrier, ivermectin is being explored as a potential therapy for aggressive brain tumors like glioblastoma.

Challenges and Future Research Directions

Despite its promise, several challenges must be addressed before ivermectin can be widely adopted as a cancer treatment:

  • Clinical Trials Are Needed: While preclinical studies show promise, large-scale clinical trials are necessary to determine the safety and efficacy of ivermectin for cancer patients.
  • Optimal Dosing and Safety: The doses required for anticancer effects may differ from those used for parasitic infections, necessitating further investigation into safety and potential side effects.
  • Regulatory Approval: The repurposing of ivermectin for cancer will require rigorous evaluation by regulatory agencies before it can be integrated into mainstream oncology treatments.

How Glucose Metabolism Responds To Ivermectin Usage

Ivermectin appears to influence glucose metabolism in cancer cells by targeting key metabolic pathways that tumors rely on for growth and survival. Cancer cells often exhibit aerobic glycolysis (Warburg effect), where they preferentially use glucose for energy production even in the presence of oxygen. This metabolic shift supports rapid cell proliferation, survival, and resistance to therapy.

How Ivermectin Affects Glucose Metabolism in Cancer Cells

Several preclinical studies suggest that ivermectin interferes with glucose metabolism in cancer cells through the following mechanisms:

  1. Inhibition of Glucose Uptake:
    • Ivermectin has been found to downregulate glucose transporters (GLUTs) on cancer cells, particularly GLUT1, which is often overexpressed in tumors. This reduces the ability of cancer cells to take in glucose, thereby limiting their primary energy source.
  2. Suppression of Glycolysis:
    • By interfering with key glycolytic enzymes, ivermectin disrupts the Warburg effect, leading to reduced ATP production. This can impair cancer cell proliferation and increase susceptibility to cell death.
    • Some studies indicate that ivermectin suppresses hexokinase 2 (HK2) and phosphofructokinase (PFK), two critical enzymes that drive glycolysis in cancer cells.
  3. Induction of Oxidative Stress and Mitochondrial Dysfunction:
    • Ivermectin promotes reactive oxygen species (ROS) production, leading to oxidative stress that cancer cells struggle to counteract.
    • It may also inhibit mitochondrial respiration, pushing cancer cells into an energy crisis, particularly in tumors that rely on glycolysis for survival.
  4. Modulation of the AMPK/mTOR Pathway:
    • AMP-activated protein kinase (AMPK) is a key regulator of energy balance in cells. Ivermectin has been shown to activate AMPK, which inhibits the mTOR pathway—a critical driver of cancer cell growth and metabolism.
    • This metabolic shift forces cancer cells into a low-energy state, reducing their ability to proliferate and survive under stress.

Potential Implications for Cancer Treatment

  • Increased Sensitivity to Chemotherapy: By disrupting glucose metabolism, ivermectin may make cancer cells more vulnerable to traditional treatments like chemotherapy and radiation.
  • Targeting Drug-Resistant Cancer Cells: Many drug-resistant tumors rely on altered metabolism for survival. Ivermectin’s ability to inhibit glycolysis and affect mitochondrial function could help overcome resistance.
  • Potential for Combination Therapies: Given its metabolic effects, ivermectin may be most effective when combined with other therapies that target cancer metabolism, such as metformin or glycolysis inhibitors.

Conclusion

Ivermectin’s impact on glucose metabolism in cancer cells is a promising area of research. By reducing glucose uptake, disrupting glycolysis, and inducing metabolic stress, ivermectin may contribute to the inhibition of tumor growth. However, clinical trials are needed to confirm these effects in cancer patients and to determine the most effective dosing strategies for metabolic targeting in patients.

A Potential Addition to Cancer Therapy

Ivermectin’s anticancer potential makes it an exciting candidate for re-purposing in oncology. While it is not yet a standalone cancer treatment, its ability to enhance existing therapies, target drug-resistant cancer cells, and disrupt tumor growth pathways warrants further investigation. If proven effective through clinical trials, ivermectin could prove to be a cost-effective, accessible, and complementary option for cancer patients alongside traditional treatments like chemotherapy, radiation, and immunotherapies.

As research progresses, it will be essential for oncologists and scientists to collaborate. In doing so hopefully with time we can determine the best ways to harness ivermectin’s potential while ensuring patient safety. Could ivermectin be the next breakthrough in cancer treatment for people across the globe? Only time and rigorous clinical research will tell.

Liability Statement:

The statements found within these pages have not been evaluated by the Food and Drug Administration. If a product or treatment is recommended in these pages, it is not intended to diagnose, treat, cure, or prevent any disease. The information contained herein is meant to be used to educate the reader and is in no way intended to provide individual medical advice. Medical advice must only be obtained from a qualified health practitioner.

References:

  1. Jiang L, Sun YJ, Song XH, Sun YY, Yang WY, Li J, Wu YJ. Ivermectin inhibits tumor metastasis by regulating the Wnt/β-catenin/integrin β1/FAK signaling pathway. Am J Cancer Res. 2022 Oct 15;12(10):4502-4519. PMID: 36381328; PMCID: PMC9641399.
  2. Jiménez-Gaona Y, Vivanco-Galván O, Morales-Larreategui G, Cabrera-Bejarano A, Lakshminarayanan V. Outcome of Ivermectin in Cancer Treatment: An Experience in Loja-Ecuador. Nurs Rep. 2023 Feb 22;13(1):315-326. doi: 10.3390/nursrep13010030. PMID: 36976682; PMCID: PMC10054244.
  3. Juarez M, Schcolnik-Cabrera A, Dueñas-Gonzalez A. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. Am J Cancer Res. 2018 Feb 1;8(2):317-331. PMID: 29511601; PMCID: PMC5835698.
  4. Kaur B, Blavo C, Parmar MS. Ivermectin: A Multifaceted Drug With a Potential Beyond Anti-parasitic Therapy. Cureus. 2024 Mar 12;16(3):e56025. doi: 10.7759/cureus.56025. PMID: 38606261; PMCID: PMC11008553.
  5. Tang M, Hu X, Wang Y, Yao X, Zhang W, Yu C, Cheng F, Li J, Fang Q. Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacol Res. 2021 Jan;163:105207. doi: 10.1016/j.phrs.2020.105207. Epub 2020 Sep 21. PMID: 32971268; PMCID: PMC7505114.